Pozuelo De Alarcon

• A Research Study to See How Switching from a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar … Ended
  2023-506084-34-00 5 2024-04-12 Type 2 Diabetes
• A Study of Tobemstomig/RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with … Ended
  2022-502457-34-00 4 2024-03-13 Triple-Negative Breast Cancer (TNBC)
• A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer’s Disease with Biomarkers of Inflammation Ended
  2023-505396-71-00 4 2024-03-01 Early Alzheimer’s Disease with Biomarkers of Inflammation
• Dose-response characterization of VER-01 in the treatment of patients with chronic non-specific low back pain Ended
  2023-507358-34-00 4 2024-02-13 For the treatment of patients with chronic non-specific low back pain
• THE ANTES B+ STUDY: AN OPEN-LABEL, PRAGMATIC, RANDOMIZED, CONTROLLED TRIAL OF TRIPLE THERAPY VERSUS LABA-LAMA COMBINATION TO IMPROVE CLINICA … Ended
  2023-507304-32-00 6 2024-02-09 Chronic Obstructive Pulmonary Disease
• MK-0616-013 Ended
  2022-502777-42-01 5 2024-01-16 Hypercholesterolemia
• A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma. Ended
  2023-503739-16-00 1 2023-12-20 Relapsed or refractory solid tumors or non-Hodgkin lymphoma
• RVU 120 (SEL120) to be tested in for treatment patients with solid tumors who have failed previous available standard therapy Ended
  2024-515131-30-00 4 2023-12-18 Relapsed / Refractory Metastatic or Advanced Solid Tumors
• A Phase 2 study (NEPTUNE-17) to evaluate efficacy and safety of GSK3858279 in DPNP. Ended
  2022-502313-28-00 4 2023-12-14 Diabetic Peripheral Neuropathic Pain
• A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination with a Checkpoint Inhibitor with or without Stand … Ended
  2022-502615-11-00 1 2023-11-29 Locally Advanced or Metastatic Solid Tumors
• A Ph2 dose-finding study (MARS-17) to evaluate the efficacy and safety of GSK3858279 in adults with knee osteoarthritis pain. Ended
  2022-502799-22-00 4 2023-11-29 Knee osteoarthritis pain
• A Phase IIb/III, Double-Blind, Randomised, Active-Controlled, Multi-Center, Non-Inferiority Clinical Trial, to assess the safety and immunog … Ended
  2023-508458-25-00 10 2023-11-13 COVID-19 disease
• Study of efficacy and safety of secukinumab in participants with moderate-severe rotator cuff tendinopathy Ended
  2022-502080-38-00 5 2023-10-16 Moderate to severe rotator cuff tendinopathy
• A study to test the effect of Samuraciclib in Combination with Elacestrant in Participants with Hormone Receptor-positive (HR+) and Human Ep … Ended
  2023-503846-30-00 9 2023-10-10 Breast Cancer
• A Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis Ended
  2022-501621-20-00 5 2023-10-02 Prurigo Nodularis
• A Phase 3 Study of Obexelimab in Patients with Warm Autoimmune Hemolytic Anemia Ended
  2022-501005-12-00 5 2023-09-22 WARM AUTOIMMUNE HEMOLYTIC ANEMIA
• A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis Ended
  2022-501476-25-00 5 2023-09-12 Atopic Dermatitis Eczema
• APTIVATE Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with … Ended
  2023-503244-14-00 7 2023-08-11 Relapsed or Refractory Acute Myeloid Leukemia (AML)
• A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with i … Ended
  2023-508267-69-00 3 2023-08-11 Subjects with Aadvanced solid tumors for whom life-prolonging therapie
• A Study of Daily Oral Orforglipron Compared with Insulin Glargine in Participants with Type 2 Diabetes and Obesity or Overweight at Increase … Ended
  2022-502833-25-00 5 2023-08-02 Obesity
• A Multicenter, Open-label Phase 1/2 Study of TYRA 300 in Advanced Urothelial Carcinoma and Other Solid Tumors Ended
  2023-507589-22-00 7 2023-07-28 Advanced Urothelial Carcinoma and Other Solid Tumors with Activating F
• Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Ended
  2024-512554-15-00 5 2023-06-21 COVID-19
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab Monotherapy in Moderate-to-severe AD (ROCKET-Ignite) Ended
  2022-501540-15-00 5 2023-04-25 Atopic Dermatitis
• Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended
  2022-501063-41-00 5 2023-04-20 Chronic Obstructive Pulmonary Disease (COPD)

Showing 265–288 of 344 trials